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Abstract
Background: Obsessive-compulsive disorder (OCD) has a lifetime prevalence of 2–3% and is a leading cause of global
disability. Brain circuit abnormalities in individuals with OCD have been identified, but important knowledge gaps
remain. The goal of the new global initiative described in this paper is to identify robust and reproducible brain
signatures of measurable behaviors and clinical symptoms that are common in individuals with OCD. A global approach
was chosen to accelerate discovery, to increase rigor and transparency, and to ensure generalizability of results.
Methods: We will study 250 medication-free adults with OCD, 100 unaffected adult siblings of individuals with OCD,
and 250 healthy control subjects at five expert research sites across five countries (Brazil, India, Netherlands, South
Africa, and the U.S.). All participants will receive clinical evaluation, neurocognitive assessment, and magnetic resonance
imaging (MRI). The imaging will examine multiple brain circuits hypothesized to underlie OCD behaviors, focusing on
morphometry (T1-weighted MRI), structural connectivity (Diffusion Tensor Imaging), and functional connectivity
(resting-state fMRI). In addition to analyzing each imaging modality separately, we will also use multi-modal fusion with
machine learning statistical methods in an attempt to derive imaging signatures that distinguish individuals with OCD
from unaffected siblings and healthy controls (Aim #1). Then we will examine how these imaging signatures link to
behavioral performance on neurocognitive tasks that probe these same circuits as well as to clinical profiles (Aim #2).
Finally, we will explore how specific environmental features (childhood trauma, socioeconomic status, and religiosity)
moderate these brain-behavior associations.
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Discussion: Using harmonized methods for data collection and analysis, we will conduct the largest neurocognitive
and multimodal-imaging study in medication-free subjects with OCD to date. By recruiting a large, ethno-culturally
diverse sample, we will test whether there are robust biosignatures of core OCD features that transcend countries and
cultures. If so, future studies can use these brain signatures to reveal trans-diagnostic disease dimensions, chart when
these signatures arise during development, and identify treatments that target these circuit abnormalities directly. The
long-term goal of this research is to change not only how we conceptualize OCD but also how we diagnose and treat
it.
Keywords: Obsessive-compulsive disorder, Neuroimaging, fMRI, Unaffected siblings, Brain signatures, Neurocognitive,
Global mental health
Background
Obsessive-compulsive disorder (OCD) has a lifetime
prevalence of 2–3% [1, 2] and results in reduced quality
of life [3, 4], lower educational attainment [5], suicidality
[6, 7], and even premature death [8, 9]. A leading global
cause of disability [10, 11], OCD contributes to signifi-
cant economic burden [12] that is expected to increase
over the next 20 years [13]. Even among individuals who
receive evidence-based treatments [14], only some
achieve remission [15, 16]. One contributor to poor out-
comes might be variation in neurobiological mechanisms
that underlie different symptom profiles; addressing this
variation with targeted treatments should improve care.
To begin to address this public health challenge, we
launched an international collaboration with two spe-
cific aims. Our first aim is to identify reproducible
brain signatures that distinguish individuals with
OCD from unaffected siblings and healthy control
subjects. Our second aim is to link these brain signa-
tures to neurocognitive and clinical profiles observed
in individuals with OCD. This approach is consonant
with the United States (U.S.) National Institute of
Mental Health’s initiative on Research Domains Cri-
teria (RDoC). The RDoC initiative seeks to develop a
research classification system for psychopathology
based on dimensions of neurobiology and observable
behavior and to use these dimensions as targets for
treatment development [17]. Our success could ultim-
ately lead to the development of objective methods
for diagnosing OCD and identifying new treatment
targets for it, with relevance to diverse populations
across the globe. Moreover, since some OCD symp-
tom profiles overlap with those seen in anxiety disor-
ders and other obsessive-compulsive-related disorders,
the data generated by this study may pave the way
for a transdiagnostic understanding of these brain-
behavior associations and enable longitudinal studies
that identify the point at which these brain signatures
arise during development. This paper provides the ra-
tionale for our study design and describes our re-
search methods.
Rationale
Why study OCD?
The clinical hallmarks of OCD are obsessions and com-
pulsions. Obsessions include repetitive unwanted
thoughts, images, impulses, or urges that typically gener-
ate distress; compulsions are repetitive behaviors or
mental acts that the individual feels driven to perform
[18]. In addition, up to 60% of individuals with OCD ex-
perience sensory phenomena, which are defined as sub-
jective experiences that precede compulsions, and can
include physical sensations, just-right sensations, and
feelings of incompleteness [19–21]. Across countries and
cultures, obsessions and compulsions cluster around
common themes known as symptom dimensions. These
dimensions include: concerns about contamination and
cleaning compulsions; fear of harm and checking com-
pulsions; need for symmetry/exactness and repeating, or-
dering, and counting compulsions; and forbidden or
taboo thoughts (e.g., aggressive, sexual, religious obses-
sions) and related compulsions [22–24]. Because the
core behaviors that characterize OCD—obsessions and
compulsions—are relatively stereotyped across countries
and cultures, focusing on this disorder offers an excel-
lent test of the ability to use objective methods to iden-
tify reproducible brain circuit abnormalities that are
linked to this discrete psychopathology.
Another reason to focus on OCD is that the imaging
literature has identified a relatively consistent pattern
of brain circuit abnormalities related to the disorder.
Specifically, dysregulation of cortico-striatal-thalamo-
cortical (CSTC) circuits is thought to underlie OCD
symptoms [25, 26]. Neuroimaging studies [27] have
identified structural and functional abnormalities in
multiple nodes of these CSTC circuits, including the
frontal cortices, the striatum, and the thalamus [25, 28].
Abnormalities in limbic and fronto-parietal circuits
have also been identified, and recent studies implicate
the cerebellum [25, 26, 29–33]. These different circuits
are depicted in Fig. 1, along with some of the key
cognitive and behavioral processes that these circuits
subserve [26].
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However, prior imaging studies have important limita-
tions that our study is designed to address. First, many
have been single-site studies in small and historically
Western, educated, industrialized, rich, and democratic
(WEIRD) samples [27], and reproducibility of findings
across sites has been variable. Meta- and mega-analyses
(like those done by the OCD Brain Imaging Consortium
(OBIC) and the initiative for Enhancing Neuroimaging
and Genetics through Meta-analyses (ENIGMA) [34–
37]) have been conducted, resulting in very large sam-
ples. These analyses pool existing data from multiple
sites that use different inclusion criteria, clinical mea-
sures, and imaging methods. This variation not only in-
troduces potential confounds, but also precludes linking
brain findings to detailed cognitive or clinical profiles
because of the lack of harmonization of such measures.
Second, most large-scale studies have been anatomical
[33], examining brain volume only. Few large-scale stud-
ies have used diffusion weighted imaging (DWI) to as-
sess structural connectivity [38–43] or resting state
functional MRI (rs-fMRI) to assess functional connectiv-
ity [41, 44–54]. Moreover, existing DWI and rs-fMRI
studies in OCD have used different acquisition and/or
analytic methods, making lack of replication hard to in-
terpret. In addition, many OCD subjects were on psy-
chotropic medication at the time of imaging, despite the
known effects on morphometry [37], DWI [55, 56], and
rs-fMRI measures [47, 57].
Third, few studies have analyzed these imaging modal-
ities in combination, despite the increasing recognition
that multi-modal analysis of imaging data can help
identify brain-behavior links [58]. Finally, although some
single-site studies report significant correlations between
brain circuit abnormalities (using DWI and rs-fMRI)
and different neurocognitive [43] and clinical profiles
[47, 59], the reproducibility of these findings needs
rigorous testing across larger and more diverse popula-
tions using harmonized methods not only for brain im-
aging, but also for clinical phenotyping and
neurocognitive testing [60].
To address these limitations, we will recruit 250
medication-free individuals with OCD, 100 unaffected
siblings of individuals with OCD, and 250 healthy con-
trol subjects (HCs) at five expert research sites that span
five countries (Brazil, India, Netherlands, South Africa,
U.S.; see Fig. 2). Using imaging methods chosen expli-
citly because of their potential adaptation for clinical
use, we will examine multiple brain circuits thought to
underlie OCD behaviors, focusing on morphometry (T1-
weighted MRI), structural connectivity (DWI), and func-
tional connectivity (rs-fMRI).
Our first aim is to identify imaging signatures that dis-
tinguish individuals with OCD from unaffected siblings
and HCs; we will accomplish this by analyzing each mo-
dality with standardized protocols and by using multi-
modal fusion with modern machine learning statistical
methods. We hypothesize that individuals with OCD will
show altered structure and function within specific
frontal-striatal, frontal-limbic, and frontal-parietal cir-
cuits. Our second aim is to then link these imaging sig-
natures both to behavioral performance on cognitive
tasks that probe these same circuits and to discrete
Fig. 1 Multiple Brain Circuits Contribute to OCD
Simpson et al. BMC Psychiatry           (2020) 20:68 Page 3 of 14
clinical profiles. We hypothesize that imaging signatures
capturing different circuit abnormalities will correlate
with behavioral performance on cognitive tasks that
probe these same circuits as well as with discrete clinical
profiles. Given the ethno-socio-cultural diversity of our
sample, we will also explore how specific environmental
features (childhood trauma, socioeconomic status, and
religiosity) may moderate these brain-behavior links.
Why take a global approach?
Although OCD and its core features are observed across
the globe, the specific presentation of OCD varies
among individuals. Specifically, patients differ from one
another both in the specific content of their OCD symp-
toms and in many other clinical features, including
symptom severity, age of onset, course of illness, degree
of insight, comorbidity, family history, and degree of
functional impairment [61–64]. Some have reported that
this variation in clinical presentation is reflected in dif-
ferent brain abnormalities [10, 27, 62, 65–68]. However,
other differences in disease expression may be better ex-
plained by specific environmental and cultural factors.
Therefore, recruiting a large, ethno-culturally diverse
sample will enable us to test whether there are robust
biosignatures of specific OCD clinical profiles that tran-
scend countries and cultures and that could be used as
targets for new treatments with relevance to populations
across the globe.
Our sites were chosen for multiple reasons. First, all
have expertise in OCD as well as the necessary clinical
and imaging research infrastructure. Second, all can re-
cruit an OCD sample that is similar in core OCD fea-
tures and educational levels, yet diverse in socio-cultural
features, enabling us to test how robust and replicable
our imaging signatures are. Third, all can recruit
medication-free OCD subjects in a timely and econom-
ical way, enabling us to collect this large sample within
the funding boundaries of a single R01 from NIMH.
Fourth, each is a center of excellence for research, train-
ing, and treatment of OCD in its respective country.
Thus, our findings will have both local and global
impact.
Finally, these sites had a successful track record of
working together. For example, the Principal Investiga-
tors have worked together to revise the guidelines for
the World Health Organization for OCD and Related
Disorders [62] and have also collaborated in the
ENIGMA-OCD consortium [69]. By joining forces for
this study, we seek to shift the research model from local
to global expertise, increase rigor and transparency, and
accelerate discovery by developing a circuit-based ap-
proach to cognitive and clinical dimensions.
Why include siblings?
Given the high heritability of OCD [28], we will also in-
clude in our sample individuals who have a biological
sibling with OCD but do not have OCD themselves
Fig. 2 The Five Collaborating Sites
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(“unaffected” siblings). This approach has been used suc-
cessfully in several prior imaging and neurocognitive
studies in OCD [41, 54, 70–74]. Including unaffected
siblings will support and strengthen our primary aims by
allowing us to identify: (1) brain abnormalities that are
present in OCD patients but not in their unaffected sib-
lings or HC subjects (helping to define brain signatures
that are most strongly linked to the disease state); (2)
brain abnormalities that OCD patients and unaffected
siblings share compared to matched HCs (helping to de-
fine brain signatures that may be linked to disease vul-
nerability); and (3) brain differences that are found in
unaffected siblings but in neither HCs nor OCD patients
(providing possible clues about resilience or compensa-
tory brain mechanisms in unaffected siblings).
Why include environmental variables in a brain imaging
study?
Some differences in OCD disease expression are hypoth-
esized to be driven more by the local environment or
contextual factors (e.g., relative severity of specific symp-
tom dimensions, specific religious beliefs, degree of im-
pairment/quality of life) than biology per se [75–78].
However, these factors have neither been examined in a
large global sample, nor correlated with imaging and
neurocognitive profiles. To begin to address this gap, we
will use clinical assessments to explore disease expres-
sion across the sites. In addition, we will examine three
specific environmental factors— childhood trauma, so-
cioeconomic status (SES), and religiosity— to determine
if they moderate the link between our neuroimaging sig-
natures and clinical and cognitive profiles. We will focus
on childhood trauma and SES because they have been
identified as environmental risk factors for OCD [79–
81]. Moreover, they have known effects on brain struc-
ture in healthy people [82–84], the potential to confound
imaging data [83, 85–90], and have been positively asso-
ciated with larger right orbitofrontal cortex volume in
individuals with OCD [91]. Religiosity (defined as the sa-
lience of religious experience in a person’s life) has been
associated with higher OCD symptoms, regardless of re-
ligion, and will thus also be explored within this multi-
cultural study context. Finally, we will capitalize on this
large and international sample to collect qualitative data
with the Cultural Formulation Interview (CFI) [92] to
explore the role of culture in the presentation and un-
derstanding of illness in those with OCD.
Methods
Study design
This project is an observational study that includes brain
imaging and clinical and neurocognitive assessments, as
described below.
Setting(s)
This study is being conducted at five expert OCD re-
search sites, including: the Obsessive-Compulsive
Spectrum Disorders Program led by Drs. Euripedes
Miguel and Roseli Shavitt at the Institute and Depart-
ment of Psychiatry, Hospital das Clinicas-HCFMUSP,
University of São Paulo Medical School in São Paulo,
Brazil; the OCD program led by Dr. Janardhan Reddy
at the National Institute of Mental Health and Neuro-
sciences in Bangalore, India; the Neuropsychiatry sec-
tion led by Dr. Odile van den Heuvel at the
Department of Psychiatry/Anatomy & Neurosciences,
Amsterdam University Medical Centers (location Free
University (VU) Medical Center) in collaboration with
the Anxiety and OCD Program of Mental Health In-
stitute GGZ inGeest, Amsterdam, the Netherlands;
the OCD program led by Drs. Dan Stein and Chris-
tine Lochner at the South African Medical Research
Council Unit on Risk and Resilience in Mental Disor-
ders in Cape Town, South Africa; and the Center for
OCD and Related Disorders led by Dr. Helen Blair
Simpson at the New York State Psychiatric Institute/
Columbia University, New York, NY, USA. All sites
have experience conducting OCD research as well as
the necessary clinical research and imaging infrastruc-
ture (e.g., 3.0 T MRI machines).
This project uses a collaborative leadership model,
with Dr. Simpson as the contact PI for NIMH. The
executive committee is comprised of the principal in-
vestigators (PIs) at each site and their key personnel;
each PI is responsible for the study at his or her site,
and the committee meets by videoconference twice
per month. Each site will recruit the same number of
subjects and use harmonized methods for clinical as-
sessment, neurocognitive testing, and imaging acquisi-
tion. The institutional review board or ethics board at
each site (named above) has reviewed and approved
the study procedures. All subjects will provide written
informed consent prior to participation.
Subjects
A total of 250 medication-free OCD patients, 100 un-
affected siblings, and 250 healthy control subjects will
be recruited across all five sites (50 OCD patients, 50
healthy control subjects, and 20 unaffected siblings
per site). The OCD and healthy control samples will
be matched on age, gender, and educational level
(within and between sites). Inclusion and exclusion
criteria are outlined in Table 1. OCD subjects must
have OCD as their principal diagnosis with at least
moderate severity. Unaffected siblings must have a
first-degree sibling with OCD but not meet criteria
for OCD themselves.
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Measures
Screening for eligibility
To determine eligibility, a trained rater will conduct a
clinical evaluation with the Structured Clinical Interview
for DSM-5 (SCID) to confirm diagnosis, the Yale-Brown
Obsessive-Compulsive Scale (Y-BOCS) [93, 94] to assess
OCD severity, and an assessment of IQ. Screening will
also include questions about treatment history, medical
history, family psychiatric history, and tic disorder.
Those eligible and interested will be enrolled after pro-
viding written informed consent.
Standardizing assessment of IQ presented a significant
challenge given that no single IQ measure has been vali-
dated across all five countries and languages. Conse-
quently, each site selected a measure of IQ that has been
validated in the appropriate languages for its respective
country and can yield a general IQ score as well as an
estimate of performance and verbal domains (Brazil:
Wechsler Abbreviated Scale of Intelligence First Edition
(WASI-I) [95]; India: Binet Kamat Test [96];
Netherlands: selected subscales from the Wechsler Adult
Intelligence Scale Fourth Edition (WAIS-IV) [97]; South
Africa: Wechsler Abbreviated Scale of Intelligence Sec-
ond Edition (WASI-II) [98]; USA: WASI-II). The IQ test
will be administered by trained raters at each site.
Clinical evaluations
A standardized protocol will be used at all sites to
clinically assess subjects in their respective language
(i.e., Afrikaans, Dutch, English, Kannada, or Portu-
guese). This protocol will include the Common Data
Elements required by NIMH as well as validated clin-
ical measures that have been used around the globe
and that tap different clinical profiles common in in-
dividuals with OCD. In addition, validated measures
of trauma history, SES, and religiosity will also be
used. These measures are shown in Table 2 and in-
clude semi-structured interviews performed by a
trained rater and self-report questionnaires. We will
also collect qualitative data using the Cultural Formu-
lation Interview (CFI) [92] to explore the role of cul-
ture in the presentation and understanding of illness
in those with OCD.
Neurocognitive assessment
Trained experimenters at each site will assess subjects
using a computerized neurocognitive protocol. Tasks
were chosen that are: 1) valid (i.e., known to probe
brain circuits and domains of cognitive dysfunction
that are implicated in OCD (see Fig. 1); 2)
generalizable (i.e., in the public domain and with min-
imal reliance on language); 3) reproducible (i.e., com-
puterized and standardized); and 4) consonant with
the NIMH’s RDoC matrix [113]. The brain circuits
and domains of cognitive function that these tasks
will probe are shown in Table 3. All tasks will be
completed outside of the scanner.
Although imaging studies in healthy subjects have
shown that these tasks probe the brain circuits impli-
cated in OCD, prior OCD studies have revealed
mixed behavioral effects with these tasks, with only
some finding behavioral deficits in individuals with
OCD relative to healthy control subjects [129–131].
There are many potential reasons for these mixed re-
sults, including the fact that studies used different
task versions and many tested OCD subjects who
were taking medication and/or had different types of
comorbid conditions. Moreover, not all prior studies
measured and controlled for IQ [132]. Finally, if the
behavioral deficits are subtle, they will be more diffi-
cult to detect consistently across samples, especially if
samples are small. In the current study, we attempt
to address these limitations by using computerized
and standardized task versions, only testing subjects
who are medication-free, measuring IQ, and recruiting
a large sample.
Table 1 Inclusion and Exclusion Criteria
OCD (n = 250) Unaffected Siblings (n = 100) Healthy Controls (n = 250)
Inclusion
Criteria
• 18–50 years old
• Principal diagnosis of OCD
• YBOCS ≥16
• 18–50 years old
• Has sibling with OCD
• 18–50 years old
Exclusion
Criteria
• Lifetime diagnosis of psychosis, bipolar
disorder, anorexia, autism, or Tourette disorder
• Current chronic tic disorder, substance-use dis-
order, binge-eating disorder, bulimia, or
suicidality
• Current use of psychotropic medications or
CBT for OCD
• Current or lifetime psychiatric
disorder other than MDD or anxiety
disorders
• Current use of psychotropic
medications
• Current or lifetime psychiatric disorder other
than MDD or anxiety disorders (if not in past
year)
• Current or past use of psychotropic
medications
• First-degree relative with OCD or tic disorder
• Major medical or neurological diseases
• IQ < 80
• Contraindications to MRI
OCD Obsessive-compulsive disorder, YBOCS Yale-Brown Obsessive-Compulsive Severity Scale, CBT Cognitive-behavioral therapy, IQ Intelligence quotient, MRI
Magnetic resonance imaging, MDD Major depressive disorder
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MRI imaging
All subjects will undergo multi-modal MRI in a 3.0
Tesla whole-body scanner equipped with a 32-channel
(or 48-channel at the U.S. site) phased-array head
coil. Details about the MRI scanners and sequences
are provided in Table 4. Sequences include: 1) high-
resolution 3D T1 weighted structural imaging using
MPRAGE according to the ADNI3 protocol with 1
mm isotropic resolution; 2) multi-shell diffusion
weighted imaging (DWI), and 3) resting-state fMRI
(10 min, eyes closed). In addition, we added a high-
resolution 3D phase-sensitive inversion recovery
(PSIR) sequence to optimize segmentation of deep
grey matter structures. All image processing will be
conducted by the Netherlands site using processing
scripts developed by the Netherlands site and EN-
IGMA [69].
We chose standard imaging sequences for structural
and functional imaging, which are commercially avail-
able or feasible to implement on most clinical scan-
ners. Our rationale was that overly specialized
paradigms that can be conducted only in a few
WEIRD [27] laboratories will have limited clinical im-
pact across most of the world. In contrast, if we
Table 2 Clinical Domains and Measures
Clinical Domains Measures
Obsessive-Compulsive Profiles
Total Severity Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) [93, 94]; Obsessive-Compulsive Inventory-Ra [99]
Dimension
Severity
Dimensional Yale-Brown Obsessive-Compulsive Scale (DY-BOCS) [100]
Insight Brown Assessment of Beliefs Scale (BABS) [101]
Sensory
Phenomena
University of São Paulo Sensory Phenomena Scale (USP-SPS) [102]
Age of Onset Structured Clinical Interview for DSM-5 (SCID) [103]; Center for OCD and Related Disorders Age of Onset and Course Form
Depression Hamilton Depression Rating Scale (HAM-D) [104]
Anxiety Hamilton Anxiety Rating Scale (HAM-A) [105]
Other Clinical
Profiles
Autism Spectrum Quotienta [106]; Center for OCD and Related Disorders Tic Questionnaire; Disgust Propensity and Sensitivity
Scalea [107]; Impulsive-Compulsive Behaviours Checklista [108]; Obsessive-Compulsive Personality Disorder Questionnaire
Functioning World Health Organization Disability Assessment Schedule 2.0 (WHODAS) [109]
Environmental
Socioeconomic
Status
Work and Meaning Inventory (WAMI)a [110];
Trauma Childhood Trauma Questionnairea [111]
Religiosity Religious Behaviors and Beliefs Questionnairea [112];
aSelf-report measure; all other measures are administered by a trained clinician
Table 3 Cognitive Tasks and Domains
Brain Circuit Cognitive Domain Cognitive Task Outcomes
Dorsal
“cognitive”
CSTCa
Working Memory Visual Spatial N-Back [71] Percent of correct trials overall and per condition
Planning Tower of London [114, 115] Percent of correct trials overall and per task load
Ventral
“cognitive”
CSTCa
Response Inhibition Stop-Signal [70, 116, 117] Stop signal reaction time
Ventral
“reward” CSTC
Reward Processing Temporal Discounting [118–
121]
Discount rate parameter on the intertemporal choice task [and risk
aversion parameter on the risk aversion task]
Frontal-Limbic Emotion Regulation /
Executive Control
Emotional Stroop [115, 122] Mean reaction time and Stroop effect
Sensorimotor
CSTC
Motor Learning Motor Sequencing [123–
126]
Learning rate, speed and accuracy, variability in motor performance
Combination of
CSTC
Reward learning /
Decision Making
Two Stage Reinforcement
Learning [127, 128]
Proportion of decisions to repeat a rewarded choice vs. an unrewarded
choice following either a common or rare transition
aWith the frontoparietal network
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identify robust biosignatures of psychopathology
across countries/cultures using standardized imaging,
our findings can then be leveraged by many.
Study flow
The timing of the assessments and the flow of subjects
through the study are outlined in Fig. 3; the specific
measures used for each clinical domain are listed in
Table 2. The clinical assessments, neurocognitive testing,
and MRI scanning will be conducted within 7 days (and
ideally within 48 h) to be able to correlate these
measures.
Study status
The study is ongoing and currently all sites are collect-
ing data at the time of this paper’s submission.
Data analytic plan and power analysis
We will collect data from a total of 600 individuals (250
OCD, 100 unaffected siblings, and 250 HC) across five
sites. Our first aim is to identify reproducible neuroimag-
ing signatures that distinguish individuals with OCD from
unaffected siblings and healthy controls. To accomplish
this aim, each imaging modality (anatomical, DWI, and
rs-fMRI) will be analyzed using standardized protocols for
uni-modal analyses; fusion of multi-modal imaging mea-
sures using modern machine learning or multilayer ana-
lyses [58, 133] will also be used to identify data-driven
signatures that distinguish the groups. Our second aim is
to link these neuroimaging signatures to behavioral per-
formance on the cognitive tasks that probe these same cir-
cuits (Table 4) and to different clinical profiles commonly
seen in individuals with OCD (e.g., different symptom di-
mensions, degree of insight, age of onset, comorbidity).
We will also explore whether three environmental factors
(childhood trauma, social economic status, and religiosity)
moderate the link between our neuroimaging signatures
and our OCD clinical and cognitive profiles.
With 250 medication-free OCD subjects, 250 demo-
graphically matched HCs, and 100 unaffected siblings, we
will have 80% power while controlling for Type 1 error to
5% to detect effect size differences (i.e., group differences
on a standardized scale) of Cohen’s d = 0.25 between
OCD and HC groups, and d = 0.33 between unaffected
siblings and either OCD or HC subjects. We note that
even within sites (i.e., within each country) our sample size
provides > 80% power to detect effect sizes of d = 0.57 be-
tween OCD and HC subjects and d = 0.80 when compar-
ing either group to unaffected siblings. We will have 80%
statistical power to test correlations of sizes as small as
r = 0.12 across all subjects at all sites (r = 0.25 within site)
Table 4 MRI Parameters
MRI Scanner
Brazil Philips Achieva 3.0 T
India Philips Ingenia 3.0 T CX
Netherlands
GE 3.0 T Discovery MR750
South
Africa
Siemens MAGNETOM Skyra 3.0 T
U.S. GE 3.0 T SIGNA Premier
Head coil 32-channel or 48-channel#
MRI Sequences
Structural
T1
3D sagittal T1-weighted MP-RAGE according to ADNI-3
protocol (1 × 1 × 1mm resolution)
rs-fMRI T2*-weighted echo-planar images while subjects are
awake and keep their eyes closed (10 min, TR = 2200ms,
TE = 28 ms, 3.3 × 3.3 mm in-plane resolution, 3 mm slices
with 0.3 mm gap)
DWI multi-shell single spin echo DWI (80 interleaved
volumes: 7 b0, 25 b1000, 24 b2000, 24 b3000, 2.5 ×
2.5 × 2.5 mm)
PSIR T1-weighted image with improved SNR and gray-white
matter contrast (1 × 1 × 1 mm resolution)
All sites use a 32-channel head coil, except NYC which uses a 48-channel head
coil. Abbreviations: rs-fMRI Resting-state functional Magnetic Resonance
Imaging, DWI Diffusion weighted Imaging, PSIR Phase sensitive
inversion recovery
Fig. 3 Study Design
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and r = 0.18 across all OCD subjects at all sites (r = 0.40
within site). Previous studies, including our own, have
found moderate to large effect sizes (i.e., d = 0.35–0.90) in
neuroimaging measures corresponding to our OCD versus
HC hypotheses, and recent studies have found strong cor-
relations (e.g., 0.40 or greater) between neuroimaging
measures and cognitive and clinical profiles [43, 47, 59].
Hence, the current study is powered to identify previously
found or smaller effect sizes across all sites. Moreover, we
expect statistical power for detecting OCD neuroimaging
profiles to be increased through our fusion of multi-modal
imaging data with machine learning statistical methods,
which optimally combine all information on the same
individual.
Quality control
Overview
Each site will be responsible for all research procedures
at its setting and will contribute to the cross-site work-
groups as described below. The U.S. site is responsible
to NIMH for the overall conduct of the study and will
be directing the data management and statistical plan.
The Netherlands site will oversee all imaging proce-
dures, including harmonization of the imaging se-
quences, review of image quality, and image processing.
To ensure quality control and cross-site communica-
tion at all levels of the teams, we created clinical, neuro-
cognitive, and imaging workgroup workgroups, each of
which is led by one member of the executive committee
and includes at least one member from each site. Speak-
ing once or twice per month, each workgroup is respon-
sible for quality control in its domain. Specific quality
control procedures are described below.
Clinical assessments
Prior to enrolling study subjects, reliability of the clinical
raters across all sites for our diagnostic and clinical mea-
sures was confirmed, following best practices used in
prior NIMH-funded clinical trials. First, we created a
manual to standardize administration of core clinical
measures across all sites. The manual contains general
instructions for administration as well as guidelines for
rating specific items on each measure. Second, each site
provided typed transcripts of interviews completed with
actual patients, and all raters scored them to ensure that
interrater reliability was high across sites. All raters were
required to be reliable on three versions of each core
clinical measure prior to study start. Third, to ensure
ongoing interrater reliability throughout the recruitment
period, clinical raters will re-rate a random sampling of
transcribed interviews from all sites each year and attend
monthly conference calls to discuss and resolve any dis-
crepant ratings. A second call each month will be used
to discuss any other clinical issues that arise, including
questions related to recruitment and eligibility.
Neurocognitive testing
We created a manual of standard operating procedures
for the computerized neurocognitive protocol used in
the study. Sites bought laptops with the same specifica-
tions (e.g., resolution, screen size, processor, random ac-
cess memory (RAM), operating system) and
standardized the set-up of the testing rooms to ensure
that tasks would be presented consistently across sites.
Each site tested the protocol with at least five volunteers
to ensure proper use and output of the protocol, and a
member of the team also reviewed screenshots and vid-
eos of each task at each site to confirm standard presen-
tation of stimuli. Throughout study recruitment, output
from each neurocognitive task will be reviewed periodic-
ally (e.g., after the first 10 subjects at each site are en-
rolled, then after the next 20 subjects) to ensure ongoing
data quality. Members of the neurocognitive workgroup
attend up to two conference calls each month to review
administration of the tasks, discuss quality control, and
ensure that data are being properly recorded and stored.
Neuroimaging data
At study start, we harmonized MRI data collection
across the five sites so that raw MRI data (anatomical,
DWI and rs-fMRI) can be optimally pooled. We
followed established methods used in other multi-center
MRI studies to reduce between-scanner effects [34, 134–
136]. These methods included: harmonization of scan
sequence, brain coverage, and spatial resolution, as well
as assessment of scan quality using two physical phan-
toms (i.e. National Institute of Standards and Technol-
ogy (NIST) and Functional Biomedical Informatics
Research Network (fBIRN) Agar). Two traveling humans
were also scanned at all sites to assess within-subject
scanner variability.
For continued quality assurance, physical phantoms will
be scanned bi-monthly (NIST for geometry) and bi-
weekly (fBIRN Agar for temporal stability). In addition,
during the recruitment phase, all sites will send neuroim-
aging data of enrolled subjects to the Netherlands site
within 48 h after a scan is acquired. The Netherlands site
subsequently preprocesses incoming scans to check for
correct spatial and timing parameters and to further en-
sure imaging quality during the recruitment phase by vis-
ual inspection and automated image quality measures of
scanner or motion-related artefacts, scan coverage, and
signal drop-out. Preprocessing and quality assurance is
performed using open-source MRI processing suites such
as FMRIB Software Library (FSL version 6.0.1, FMRIB,
Oxford, UK), QUAD [137], and MRIQC [138]. Any anom-
alies are reported back to the site for follow-up.
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Discussion
Using harmonized methods for data collection and ana-
lysis, we will conduct the largest multimodal imaging and
neurocognitive study in medication-free adults with OCD
to date. Our study is designed to address a key question in
the field: can we identify reproducible biosignatures of
psychopathology that will change how we conceptualize
mental illness, develop a mechanistic understanding of
how current treatments work, and provide robust new tar-
gets for treatment development? As reviewed above, OCD
provides an excellent test of this question, and the study
described above represents the first step. Specifically, we
will leverage our large diverse sample, multimodal im-
aging, and modern data-driven imaging methods [58, 133]
to test whether we can empirically derive imaging signa-
tures that reliably differentiate OCD patients from un-
affected siblings and healthy controls.
With the increasing recognition of the global burden of
mental illness [67, 139] and the fact that the International
Classification of Diseases (ICD) will make OCD the lead
disorder in a new cluster that includes OCD and related
disorders [62], this is an opportune moment to focus the
global health community on OCD by conducting an inter-
national study like this. Although there have been prior
imaging and neurocognitive studies on OCD, ours will be
the first to examine a very large sample of individuals who
are free of medication and to use harmonized imaging
methods and neurocognitive tasks in accordance with the
RDoC domains. Our work will clarify whether OCD sub-
jects across the globe show altered structure and function
within frontal-striatal, frontal-limbic, and frontal-parietal
circuits, as we hypothesize. If we see the structural abnor-
malities found in several meta- and mega-analyses [34, 35,
140, 141], including that of ENIGMA-OCD [36, 37], it will
provide strong evidence for the link between these struc-
tural abnormalities and OCD psychopathology. Moreover,
we will test how multimodal imaging measures are linked
to discrete domains of neurocognitive or clinical profiles,
enabling us to make new discoveries about the association
between abnormalities in structural and functional con-
nectivity and cognitive and clinical dimensions of OCD.
Including unaffected siblings in our sample will con-
tribute important new information about the brain cir-
cuit alterations associated with OCD risk and resilience,
and we plan to recruit a sufficient sample of unaffected
siblings to have the statistical power to examine these
questions in a definitive way. Moreover, we will explore
the relationship between environmental factors (child-
hood trauma, socioeconomic status, religiosity) and the
brain signatures of OCD, as well as their potential mod-
erating effect on the relationship between these signa-
tures and OCD neurocognitive and clinical profiles.
Consequently, this study will advance our understanding
of the socio-contextual factors that influence OCD risk,
severity, and associated morbidity, providing additional
mechanisms to target for treatment and prevention.
Finally, our study is designed to strengthen the public
health impact of research through large-scale global col-
laboration. By linking our five research sites, we will be
able to recruit a large and diverse sample to examine
questions that no single site alone could address. More-
over, by leveraging our intellectual resources and meth-
odological expertise, we seek to accelerate discovery
toward a circuit-based approach to cognitive and clinical
dimensions of OCD. In the process, we integrate two dif-
ferent perspectives: that of global mental health, which
has been focused on building capacity and service delivery
in low-resource settings and closing the research and
treatment gap, and that of translational neuroscience,
which is focused on discovery of fundamental brain pro-
cesses and mechanisms underlying psychopathology and
using this knowledge to transform symptom-based ap-
proaches to diagnosis and treatment [142]). We integrate
these perspectives by selecting imaging and neurocogni-
tive measures that can be used in diverse settings (the
“World Health Organization [WHO] approach”) [66]; this
way, our findings can be leveraged by many.
Empirically derived neural circuit taxonomies repre-
sent a new direction of discovery in psychiatry, and simi-
lar statistical methods have identified distinct biotypes in
psychosis [143] as well as in depression and anxiety
[144–147]. If we successfully link different brain circuit
abnormalities to discrete cognitive and clinical profiles
that are characteristic of OCD, we will be positioned for
future study of how these brain circuit abnormalities de-
velop during the course of disease, determine how they
cut across traditional diagnostic boundaries, and use
them as robust new treatment targets. Ultimately, this
research could lead to objective methods for early diag-
nosis and intervention as well as to transdiagnostic treat-
ments, with discoveries that will be relevant to
populations across the globe.
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